Seminars in Oncology
Volume 35, Issue 6 , Pages 582-589 , December 2008

Ovarian Cancer in Older Women

  • William P. Tew

      Affiliations

    • Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
    • Corresponding Author InformationAddress correspondence to William P. Tew, MD, Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021
    • ,
  • Stuart M. Lichtman

      Affiliations

    • Department of Medicine, Memorial Sloan-Kettering Cancer Center, Commack, NY

References 

  1. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94:2766–2792
  2. Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31:128–136
  3. Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma (The Gynecologic Oncology Group experience). Cancer. 1993;71:606–614
  4. Hightower RD, Nguyen HN, Averette HE, et al. National survey of ovarian carcinoma (IV: Patterns of care and related survival for older patients). Cancer. 1994;73:377–383
  5. Pignata S, Vermorken JB. Ovarian cancer in the elderly. Crit Rev Oncol Hematol. 2004;49:77–86
  6. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  7. Ries LA, Melbert D, Krapcho M. SEER cancer statistics review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008;
  8. Watson P, Butzow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 2001;82:223–228
  9. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006;24:863–871
  10. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med. 2002;346:1660–1662
  11. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26:1331–1337
  12. Chi DS, Sabbatini P. Advanced ovarian cancer. Curr Treat Options Oncol. 2000;1:139–146
  13. Mirhashemi R, Nieves-Neira W, Averette HE. Gynecologic malignancies in older women. Oncology (Williston Park). 2001;15:580–586
  14. Lambrou NC, Bristow RE. Ovarian cancer in elderly women. Oncology (Williston Park). 2003;17:1075–1081
  15. Ryerson AB, Eheman C, Burton J, et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol. 2007;109:1053–1061
  16. Winter WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:3621–3627
  17. Chan JK, Loizzi V, Lin YG, et al. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?. Obstet Gynecol. 2003;102:156–161
  18. Chan JK, Urban R, Cheung MK, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006;95:1314–1320
  19. Markman M, Lewis JL, Saigo P, et al. Impact of age on survival of patients with ovarian cancer. Gynecol Oncol. 1993;49:236–239
  20. Petignat P, Fioretta G, Verkooijen HM, et al. Poorer survival of elderly patients with ovarian cancer: a population-based study. Surg Oncol. 2004;13:181–186
  21. Du XL, Sun CC, Milam MR, et al. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:660–669
  22. Pectasides D, Fountzilas G, Aravantinos G, et al. Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? (The Hellenic Oncology Cooperative Group experience). Int J Gynecol Cancer. 2007;17:1003–1010
  23. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–1259
  24. Wimberger P, Lehmann N, Kimmig R, et al. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2006;100:300–307
  25. Uyar D, Frasure HE, Markman M, et al. Treatment patterns by decade of life in elderly women (> or = 70 years of age) with ovarian cancer. Gynecol Oncol. 2005;98:403–408
  26. Wright JD, Herzog TJ, Powell MA. Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol. 2004;190:1398–1400
  27. Sharma S, Driscoll D, Odunsi K, et al. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol. 2005;193:2077–2082
  28. Eisenhauer EL, Tew WP, Levine DA, et al. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol. 2007;106:381–387
  29. Bruchim I, Altaras M, Fishman A. Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol. 2002;86:274–278
  30. Nordin AJ, Chinn DJ, Moloney I, et al. Do elderly cancer patients care about cure? (Attitudes to radical gynecologic oncology surgery in the elderly). Gynecol Oncol. 2001;81:447–455
  31. Cloven NG, Manetta A, Berman ML, et al. Management of ovarian cancer in patients older than 80 years of Age. Gynecol Oncol. 1999;73:137–139
  32. Susini T, Scambia G, Margariti PA, et al. Gynecologic oncologic surgery in the elderly: a retrospective analysis of 213 patients. Gynecol Oncol. 1999;75:437–443
  33. Diaz-Montes TP, Zahurak ML, Giuntoli RL, et al. Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol. 2005;99:352–357
  34. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6
  35. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–3200
  36. Maas HA, Kruitwagen RF, Lemmens VE, et al. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol. 2005;97:104–109
  37. Hershman D, Jacobson JS, McBride R, et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol. 2004;94:540–549
  38. Sundararajan V, Hershman D, Grann VR, et al. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol. 2002;20:173–178
  39. Pignata S, Monfardini S. Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma. Eur J Cancer. 2000;36:817–820
  40. Pignata S, Breda E, Scambia G, et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer (A Multicentre Italian Trial in Ovarian cancer (MITO-5) study). Crit Rev Oncol Hematol. 2008;66:229–236
  41. Tredan O, Geay JF, Touzet S, et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? (Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens). Ann Oncol. 2007;18:256–262
  42. Fader AN, Gruenigen VV, Gibbons H, et al. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol. 2008;109:33–38
  43. ICON Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360:505–515
  44. Villella JA, Chaudhry T, Pearl ML, et al. Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol. 2002;86:316–322
  45. Ceccaroni M, D'Agostino G, Ferrandina G, et al. Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? (An Italian retrospective toxicity multicentric study). Gynecol Oncol. 2002;85:445–450
  46. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–1955
  47. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–1007
  48. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43
  49. Wenzel LB, Huang HQ, Armstrong DK, et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:437–443
  50. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652–659
  51. Launay-Vacher V, Chatelut E, Lichtman SM, et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol. 2007;18:1314–1321
  52. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer. 2007;110:1376–1384
  53. Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34
  54. Lichtman SM, Hollis D, Miller AA, et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol. 2006;24:1846–1851
  55. Lichtman SM, Wildiers H, Chatelut E, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients—an analysis of the medical literature. J Clin Oncol. 2007;25:1832–1843
  56. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–2106
  57. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699–4707
  58. Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Semin Oncol. 2007;34:S1–S15
  59. Gridelli C, Langer C, Maione P, et al. Lung cancer in the elderly. J Clin Oncol. 2007;25:1898–1907
  60. Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 2007;8:1101–1115
  61. Gronlund B, Hogdall C, Hansen HH, et al. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer. 2002;94:1961–1967
  62. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8
  63. Morris RT. Weekly topotecan in the management of ovarian cancer. Gynecol Oncol. 2003;90:S34–S38
  64. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol. 2007;25:2902–2908
  65. Lewin SN, Buttin BM, Powell MA, et al. Resource utilization for ovarian cancer patients at the end of life: how much is too much?. Gynecol Oncol. 2005;99:261–266
  66. Hurria A, Lichtman SM, Gardes J, et al. Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc. 2007;55:1604–1608
  67. Freyer G, Geay JF, Touzet S, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol. 2005;16:1795–1800
  68. Moore DH, Kauderer JT, Bell J, et al. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;94:368–374

PII: S0093-7754(08)00190-5

doi: 10.1053/j.seminoncol.2008.08.007

Seminars in Oncology
Volume 35, Issue 6 , Pages 582-589 , December 2008

Article Tools